(Q33729025)

29 July 2017

1 reference

title

Current status of tamoxifen use: An update for the surgical oncologist (English)

1 reference

29 July 2017

1 reference

Heerdt AS

1

1 reference

29 July 2017

Borgen PI

series ordinal

2

1 reference

29 July 2017

publication date

1 September 1999

1 reference

Journal of Surgical Oncology

29 July 2017

published in

1 reference

29 July 2017

volume

72

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

42-49

1 reference

Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Antihormone treatment of stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Long-term followup of breast cancer patients: the 30-year report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Adjuvant chemotherapy in breast cancer—Swiss co-operative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Immunomodulation by tamoxifen and pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Anti-oestrogen therapy of advanced mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Treatment of advanced breast cancer with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Treatment of curable carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: Preliminary results—the ECOG experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Tamoxifen and benign breast problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

The prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9098%28199909%2972%3A1%3C42%3A%3AAID-JSO13%3E3.0.CO%3B2-E

10.1002/(SICI)1096-9098(199909)72:1<42::AID-JSO13>3.0.CO;2-E

21 January 2018

Identifiers

DOI

1 reference

release_go7cthvhzvhfremxzjkwklyf2a

29 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/go7cthvhzvhfremxzjkwklyf2a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference